About 13% of women in the United States will be diagnosed with breast cancer at some point in their lifetime, based on the most recent data from 2021 to 2023. That translates to roughly 1 in 8 women. But this single number hides a lot of variation. Your actual risk depends heavily on your age right now, your genetics, your breast density, and your racial or ethnic background.
How Risk Changes With Age
Breast cancer is not a single roll of the dice. Your risk accumulates over time, and it rises sharply as you get older. The National Cancer Institute breaks it down by decade, showing the probability of being diagnosed in the next 10 years starting at each age:
- Age 30: 0.49%, or 1 in 204
- Age 40: 1.55%, or 1 in 65
- Age 50: 2.40%, or 1 in 42
- Age 60: 3.54%, or 1 in 28
- Age 70: 4.09%, or 1 in 24
A 30-year-old woman has less than a half-percent chance of developing breast cancer in the next decade. By age 70, that jumps to about 4%. This is one reason screening recommendations change as you age, and why the “1 in 8” lifetime figure can feel misleading if you’re younger. It reflects cumulative risk across an entire lifespan, not the risk you face right now.
Rates Differ by Race and Ethnicity
White, non-Hispanic women have historically had the highest overall incidence of breast cancer, with a rate of about 187 per 100,000 women as of 2018. Black, non-Hispanic women follow at roughly 174 per 100,000. Asian and Pacific Islander women have the lowest rates at about 144 per 100,000, while Hispanic women fall in between at 134 per 100,000.
These gaps have been shifting, though. Rates among white women have slowly decreased over the past two decades, dropping an average of 0.3% per year. Meanwhile, rates among Asian and Pacific Islander women have been climbing about 0.8% per year since 1999, and rates among Hispanic women began rising again after 2004. Black women’s rates have remained largely stable over the same period.
Importantly, incidence tells only part of the story. Black women are more likely to be diagnosed at a later stage and have higher mortality rates than white women, even though their overall diagnosis rate is somewhat lower. Factors like access to screening, the types of breast cancer that are more common in different populations, and systemic healthcare disparities all play a role.
Genetics Can Multiply the Risk
The general population’s 13% lifetime risk assumes average genetics. Women who inherit certain gene mutations face a dramatically different picture. More than 60% of women who carry a harmful change in the BRCA1 or BRCA2 genes will develop breast cancer during their lifetime. That’s roughly four to five times the average risk.
These mutations are relatively rare. Only about 1 in 400 people in the general population carries one, though the rate is higher in certain groups, including women of Ashkenazi Jewish descent. If you have a strong family history of breast or ovarian cancer, particularly diagnoses before age 50 or multiple affected relatives on the same side, genetic counseling can help determine whether testing makes sense for you.
Breast Density as a Risk Factor
About 10% of women have what’s classified as extremely dense breast tissue, which roughly doubles their breast cancer risk compared to women with non-dense (fatty) breasts. Some earlier research found the gap could be even wider, with a four- to six-fold increase in risk for the densest category compared to the least dense. Dense tissue also makes cancers harder to spot on a standard mammogram, since both dense tissue and tumors appear white on the image.
You can’t feel breast density on your own. It’s determined by mammography, and your radiologist can tell you your density category. As of 2024, federal rules require mammography facilities to notify patients about their breast density, which may prompt a conversation about whether additional screening methods would be useful for you.
Invasive vs. Non-Invasive Cases
Not all breast cancer diagnoses are the same. About 75 to 80% of new cases are invasive, meaning the cancer has grown beyond the milk ducts or lobules into surrounding breast tissue. The remaining 20 to 25% are a non-invasive form called ductal carcinoma in situ, where abnormal cells are confined inside the milk ducts and haven’t spread. Non-invasive cases have an excellent prognosis, and many never progress to invasive cancer, though they’re typically treated to reduce that possibility.
How the U.S. Compares Globally
Breast cancer is the most commonly diagnosed cancer in women worldwide, with an estimated 2.3 million new cases in 2022. But risk is not evenly distributed across the globe. In countries with very high levels of human development, about 1 in 12 women will be diagnosed in her lifetime. In low-development countries, the figure drops to about 1 in 27.
That difference reflects a mix of factors: higher screening rates in wealthier nations catch more cases (including early-stage cancers that might go undetected elsewhere), and lifestyle factors like later childbearing, lower breastfeeding rates, and higher rates of obesity all contribute to elevated risk. Paradoxically, women in lower-income countries are more likely to die from breast cancer despite being diagnosed less often, largely because of limited access to treatment. In high-development countries, 1 in 71 women die from breast cancer. In low-development countries, it’s 1 in 48.
Men and Breast Cancer
Breast cancer in men is rare but real. The lifetime risk for men is about 1 in 755, and fewer than 1% of all breast cancer cases in the U.S. occur in men. About 2,670 men are expected to be diagnosed with invasive breast cancer in 2026. Because it’s so uncommon, men are more likely to be diagnosed at a later stage simply because neither they nor their doctors are looking for it.